title: Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum.
abstract: In a previous study we showed that 1 alpha OH vitamin D3 [1 alpha (OH)3] given to 16 hemodialyzed patients taking Al(OH)3 at a constant dose increased their plasma concentrations of aluminum [Demontis et al. 1986]. In order to choose between 2 possible mechanisms explaining this increase (increased intestinal absorption or decreased tissue storage of aluminum), we gave, in the present study, 1 alpha (OH)3 the same dose (6 micrograms per week) for the same period (4 weeks) to 15 stable hemodialyzed patients after their Al(OH)3 had been discontinued for 6 weeks. Under Al(OH)3 treatment they had a mean plasma aluminum (2.33 +/- 2.36 mumol/l) which was not significantly different from that of the patients in our former study (1.23 +/- 0.25 mumol/l). After Al(OH)3 discontinuation, plasma aluminum (measured by inductively coupled plasma emission spectrometry) decreased significantly as early as the 2nd week of the control period (1.39 mumol/l). The decrease was maintained at a plateau throughout the 5 weeks of the control period (1.38 mumol/l), the 4 weeks of 1 alpha OH vitamin (vit) D3 administration (1.40 mumol/l) and the 8 weeks of the post 1 alpha (OH)3 period (1.22 mumol/l). Plasma calcium and phosphate concentrations increased significantly with 1 alpha (OH)3 and decreased thereafter whereas plasma PTH concentrations decreased during 1 alpha (OH)2 D3 and increased after its discontinuation suggesting biological activity of 1 alpha (OH)3. Since 1 alpha (OH)3 increases plasma aluminum in hemodialyzed patients only when they are simultaneously taking Al(OH)3, it is suggested that this increase is explained by an increase of intestinal absorption of aluminum and not by a tissue redistribution of aluminum.
authors.affiliation: Nephrology Service, Centre hospitalier, St. Quentin, France.
authors.forename: R
authors.initials: R
authors.lastname: Demontis
authors.forename: D
authors.initials: D
authors.lastname: Reissi
authors.forename: C
authors.initials: C
authors.lastname: Noel
authors.forename: B
authors.initials: B
authors.lastname: Boudailliez
authors.forename: P F
authors.initials: PF
authors.lastname: Westeel
authors.forename: P
authors.initials: P
authors.lastname: Leflon
authors.forename: J
authors.initials: J
authors.lastname: Brasseur
authors.forename: B
authors.initials: B
authors.lastname: Coevoet
authors.forename: A
authors.initials: A
authors.lastname: Fournier
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000535:Aluminum / Q000097:blood / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000494:pharmacology*; D007408:Intestinal Absorption / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D006887:Hydroxycholecalciferols; D000535:Aluminum; C008088:alfacalcidol